Cargando…
A Randomized, Double‐Blind, Placebo‐Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss
OBJECTIVE: This study aims to assess the efficacy and safety of Gelesis100, a novel, nonsystemic, superabsorbent hydrogel to treat overweight or obesity. METHODS: The Gelesis Loss Of Weight (GLOW) study was a 24‐week, multicenter, randomized, double‐blind, placebo‐controlled study in patients with B...
Autores principales: | Greenway, Frank L., Aronne, Louis J., Raben, Anne, Astrup, Arne, Apovian, Caroline M., Hill, James O., Kaplan, Lee M., Fujioka, Ken, Matejkova, Erika, Svacina, Stepan, Luzi, Livio, Gnessi, Lucio, Navas‐Carretero, Santiago, Alfredo Martinez, J., Still, Christopher D., Sannino, Alessandro, Saponaro, Cosimo, Demitri, Christian, Urban, Lorien E., Leider, Harry, Chiquette, Elaine, Ron, Eyal S., Zohar, Yishai, Heshmati, Hassan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587502/ https://www.ncbi.nlm.nih.gov/pubmed/30421844 http://dx.doi.org/10.1002/oby.22347 |
Ejemplares similares
-
MON-112 Gelesis100 Reduces Insulin Resistance in Patients Who Are Overweight or Have Obesity with High Insulin Resistance: Results of the GLOW Study
por: Greenway, Frank, et al.
Publicado: (2019) -
SAT-LB023 Elevated Fasting Plasma Glucose Predicts Higher Odds For Becoming A Super-responder With Gelesis100 In The GLOW Pivotal Weight-loss Study
por: Greenway, Frank, et al.
Publicado: (2019) -
MON-LB022 Gelesis Novel, Non-Systemic, Superabsorbent Hydrogel Improves Intestinal Barrier Function in Mice with DSS Induced Colitis
por: Silvestri, Alessandra, et al.
Publicado: (2019) -
Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis
por: Takahashi, Mie, et al.
Publicado: (2017) -
Nerve Ultrasound as a Decisive Tool in Nonsystemic Vasculitic Neuropathy: A Case Report
por: Leupold, Daniela, et al.
Publicado: (2016)